Literature DB >> 17672512

Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2.

Li Liu1, Annette Von Vett, Naixia Zhang, Kylie J Walters, Carston R Wagner, Patrick E Hanna.   

Abstract

Arylamine N-acetyltransferases (NATs) are phase II xenobiotic metabolism enzymes that catalyze the detoxification of arylamines by N-acetylation and the bioactivation of N-arylhydroxylamines by O-acetylation. Endogenous and recombinant mammalian NATs with high specific activities are difficult to obtain in substantial quantities and in a state of homogeneity. This paper describes the overexpression of human wild-type NAT2 as a dihydrofolate reductase fusion protein containing a TEV protease-sensitive linker. Treatment of the partially purified fusion protein with TEV protease, followed by chromatographic purification, afforded 2.8 mg of homogeneous NAT2 from 2 L of cell culture. The kinetic specificity constants ( k cat/ K m) for N-acetylation of arylamine environmental contaminants, some of which are associated with bladder cancer risk, were determined with NAT2 and NAT1. The NAT1/NAT2 ratio of the specificity constants varied almost 1000-fold for monosubstituted and disubstituted alkylanilines containing methyl and ethyl ring substituents. 2-Alkyl substituents depressed N-acetylation rates but were more detrimental to catalysis by NAT1 than by NAT2. 3-Alkyl groups caused substrates to be preferentially N-acetylated by NAT2, and both 4-methyl- and 4-ethylaniline were better substrates for NAT1 than NAT2. NMR-based models were used to analyze the NAT binding site interactions of the alkylanilines. The selectivity of NAT1 for acetylation of 4-alkylanilines appears to be due to binding of the substituents to V216, which is replaced by S216 in NAT2. The contribution of 3-alkyl substituents to NAT2 substrate selectivity is attributed to multiple bonding interactions with F93, whereas a single bonding interaction occurs with V93 in NAT1. Unfavorable steric clashes between 2-methyl substituents and F125 of NAT1 may account for the selective NAT2-mediated N-acetylation of 2-alkylanilines; F125 is replaced by S125 in NAT2. These results provide insight into the structural basis for the substrate specificity of two NATs that play major roles in the biotransformation of genotoxic environmental arylamines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17672512     DOI: 10.1021/tx7001614

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  12 in total

1.  Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.

Authors:  Lisa F Potts; Alex C Cambon; Owen A Ross; Rosa Rademakers; Dennis W Dickson; Ryan J Uitti; Zbigniew K Wszolek; Shesh N Rai; Matthew J Farrer; David W Hein; Irene Litvan
Journal:  BMC Med Genet       Date:  2012-03-17       Impact factor: 2.103

2.  N-acetyltransferase-2 genotypes among patients with rheumatoid arthritis attending Jordan University Hospital.

Authors:  Muna K Oqal; Khader N Mustafa; Yacoub M Irshaid
Journal:  Genet Test Mol Biomarkers       Date:  2012-06-25

3.  Variation in N-acetyltransferase 2 (NAT2), smoking and risk of prostate cancer in the Slovak population.

Authors:  Marta Vilčková; Jana Jurečeková; Dušan Dobrota; Viera Habalová; Lucia Klimčáková; Iveta Waczulíková; Peter Slezák; Ján Kliment; Monika Kmeťová Sivoňová
Journal:  Med Oncol       Date:  2014-05-11       Impact factor: 3.064

4.  Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.

Authors:  Tomoko Nakai; Daisuke Sakai; Yoshihiko Nakamura; Natsumi Horikita; Erika Matsushita; Mitsuru Naiki; Masahiko Watanabe
Journal:  BMC Med Genomics       Date:  2021-03-11       Impact factor: 3.063

5.  Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).

Authors:  Pooja V Hegde; Michael D Howe; Matthew D Zimmerman; Helena I M Boshoff; Sachin Sharma; Brianna Remache; Ziyi Jia; Yan Pan; Anthony D Baughn; Veronique Dartois; Courtney C Aldrich
Journal:  Eur J Med Chem       Date:  2022-02-19       Impact factor: 6.514

6.  Screening reactive metabolites bioactivated by multiple enzyme pathways using a multiplexed microfluidic system.

Authors:  Dhanuka P Wasalathanthri; Ronaldo C Faria; Spundana Malla; Amit A Joshi; John B Schenkman; James F Rusling
Journal:  Analyst       Date:  2012-10-25       Impact factor: 4.616

Review 7.  N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.

Authors:  David W Hein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

Review 8.  Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1.

Authors:  Jason M Walraven; John O Trent; David W Hein
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

9.  Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes.

Authors:  Carmine S Leggett; Mark A Doll; J Christopher States; David W Hein
Journal:  Arch Toxicol       Date:  2020-11-02       Impact factor: 5.153

10.  Comparative analysis of xenobiotic metabolising N-acetyltransferases from ten non-human primates as in vitro models of human homologues.

Authors:  Theodora Tsirka; Maria Konstantopoulou; Audrey Sabbagh; Brigitte Crouau-Roy; Ali Ryan; Edith Sim; Sotiria Boukouvala; Giannoulis Fakis
Journal:  Sci Rep       Date:  2018-06-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.